Effects of Elaeagnus angustifolia L. on the sex hormone profiles in menopause women

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017030932795N2

Enrollment

Registered

2017-09-11

Start date

2017-08-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menopause. Menopausal and perimenopausal disorder, unspecified

Interventions

Intervention 1: Intervention group:Elaeagnus angustifolia L powder, 15 g / day. Intervention 2: Control group (placebo): 7.5 g Isomalt and 7.5 g Corn starch / day.

Treatment - Drugs

Intervention group:Elaeagnus angustifolia L powder, 15 g / day

Control group (placebo): 7.5 g Isomalt and 7.5 g Corn starch / day

Eligibility

Sex/Gender

Female

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: All women aged 40-70 with serum lipid levels of 200-300 mg/dl without any risk factor for not using medicine to decrease the lipid level are included in this trial. Exclusion criteria: The women who suffer from ccardiovascular diseases, renal and metabolic disorders such as diabetes, those using psychiatric drugs, smoking tobacco or consuming alcohol or narcotic agents are excluded from the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Estradiol. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical Diagnostic Laboratories.;Progesterone. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical Diagnostic Laboratories.;Testosterone. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical Diagnostic Laboratories.;FSH (Follicle stimulating hormone). Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical Diagnostic Laboratories.;LH (Luteinizing hormone). Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic Laboratories.	—

Measure

Time frame

Estradiol. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical Diagnostic Laboratories.;Progesterone. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical Diagnostic Laboratories.;Testosterone. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical Diagnostic Laboratories.;FSH (Follicle stimulating hormone). Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical Diagnostic Laboratories.;LH (Luteinizing hormone). Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic Laboratories.

—

Secondary

Measure	Time frame
Constipation. Timepoint: After the start of the trial and up to 10 weeks after taking the drug. Method of measurement: Questionnaire and weekly phone calls.;Abdominal Pain. Timepoint: After the start of the trial and up to 10 weeks after taking the drug. Method of measurement: Questionnaire and weekly phone calls.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzaneh Emami Nia

Damghan University

farzaneh.emaminia@gmail.com+98 21 7744 7318

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026